BXCL701
A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 24 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Tags
- Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1488
- NCT Identifier
- NCT05703542
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.